SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Remus Pharmaceuticals Ltd

BSE: 0 NSE: REMUS ISIN: INE0O5T01011
  |   Sector:  Miscellaneous   |   Industry:  Trading

Snapshot

Q.1 Which industry/sub-sector does Remus Pharmaceuticals Ltd belong to?
Remus Pharmaceuticals Ltd belongs to the Miscellaneous sector, operating specifically within the Trading segment.
Q.2 Is Remus Pharmaceuticals Ltd a good quality company?
Remus Pharmaceuticals Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Remus Pharmaceuticals Ltd undervalued or overvalued?
Remus Pharmaceuticals Ltd appears Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Remus Pharmaceuticals Ltd a good buy now?
Remus Pharmaceuticals Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd revenue growth is 23.8% for FY-2025 , which is below its 5 year CAGR of 46% , indicating slower growth.
Q.2 Gross Profit margin of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 36% for FY-2025 , which is above its 5 year median of 26.4% , indicating increasing margins.
Q.3 Operating Profit Margin of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 32.82% for FY-2025 , which is above its 5 year median of 23.42% indicating increasing margins.
Q.4 Net Profit Margin of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd Net Profit Margin is 25.14% for FY-2025 , is above with its 5 year median of 18.88%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 36 26.4
Operating Profit Margin 32.82 23.42
Net Profit Margin 25.14 18.88
Q.5 Return on Asset of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd Return on Asset is 8.58%, which is below its 5 year historical median of 15.25%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd Return on equity is 10.06% for FY-2025 , which is below its historical median of 40.49%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd Return on capital employed is 13.53% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd Cash conversion cycle is 30 days, above its historical median of -7 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.34 1.79
ROE 10.06 40.49
ROCE 13.53 48.84
Cash Conversion Cycle 30 days -7 days
Q.9 Debt to Equity ratio of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd Debt-to-Equity ratio is 0.01 , which is lower with the industry average of 0.03 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd Debt to cash flow from operations is 0.14 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Remus Pharmaceuticals Ltd?
Promoters hold 70.91% of the Remus Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Remus Pharmaceuticals Ltd vs industry peers?
Remus Pharmaceuticals Ltd revenue CAGR is 46.03% , compared to the industry median CAGR of 0% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 79.2 13.3
Gross Profit 28.4 0.4
Operating Profit 26 0
Net Profit 20 0.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.34 0.5
ROE 10.06 2.03
ROCE 13.53 3.6
Cash Conversion Cycle (days) 30.15 41

Valuation & price assessment

Q.1 Stock return of Remus Pharmaceuticals Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -67.56% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - - -67.6%
Q.3 Valuation ratios of Remus Pharmaceuticals Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 38.49 66.26 21.75
Price to Book 3.09 12.89 1.55
Price to Sales 9.68 17.55 1.87
EV to EBITDA 26.44 47.15 13.67

Check more companies

1. Aditya Infotech
2. Aegis Logistics
3. Redington
4. RRP Semiconductor
5. Honasa Consumer
6. MMTC
7. Lloyds Enterprises
8. Cello World
9. Jeena Sikho Life
10. Elitecon Internation
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×